Comparing group therapy and individual therapy to prevent repeat suicide attempts
Cognitive Behavioural Group Therapy Versus Individual Supportive Therapy for the Prevention of Repeat Suicide Attempts: a Multicentre, Assessor-blinded, 2-parallel-group, Randomised, Superiority Trial
This study is testing whether group therapy or individual therapy is better at helping adults who have attempted suicide avoid doing it again after being hospitalized.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Locations | 9 sites (Clermont Ferrand and 8 other locations) |
| Trial ID | NCT02664701 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Cognitive Behavioural Group Therapy (CBGT) compared to Individual Supportive Therapy (IST) in preventing repeat suicide attempts among adults who have been hospitalized for suicide attempts. Participants will undergo six sessions of either therapy, with assessments conducted at baseline and follow-up to measure outcomes such as incidence of suicide attempts, suicidal ideation, and psychiatric symptoms over a 12-month period. The study aims to provide insights into the long-term benefits of these therapeutic approaches in reducing the risk of suicide.
Who should consider this trial
Good fit: Ideal candidates are French-speaking adults aged 18 and older who have recently attempted suicide and are at medium to high risk for future attempts.
Not a fit: Patients who are not French-speaking or those who have not recently attempted suicide may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of repeat suicide attempts and improve mental health outcomes for at-risk individuals.
How similar studies have performed: Previous studies have shown promising results for cognitive behavioral therapies in reducing suicidal ideation and attempts, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patient has been correctly informed * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * French speaking adults (18 years or older) freely hospitalized (in centres or via emergency services) for prevention of suicide and who have a medium or high suicide risk score according to a Mini International Neuropsychiatric Interview structured interview * Presence of suicidal ideation according to the Beck Suicide Ideation Scale (score \> 3) * Prior (or recent) suicide attempt within the last three month * The patient is able to understand the study and capable of giving his/her informed consent * The patient is available during the weekly time slots proposed by the investigator Exclusion Criteria: * The patient is participating in another study that may interfere with the results or conclusions of this study * Within the past three months, the patient has participated in another study that may interfere with the results or conclusions of this study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, or is an adult under guardianship * The patient refuses to sign the consent, or it is impossible to correctly inform the patient * Emergency situations preventing proper study conduct * History of schizophrenia or other psychotic troubles * Presence of psychotic symptoms at initial interview * Serious cognitive impairment * Medical incapacity to participate
Where this trial is running
Clermont Ferrand and 8 other locations
- CHU de Clermont Ferrand - Hôpital Gabriel-Montpied — Clermont Ferrand, France (Not_yet_recruiting)
- CHU de Lyon - Groupement Hospitalier Edouard Herriot — Lyon Cedex 3, France (Not_yet_recruiting)
- CHRU de Montpellier - Hôpital Lapeyronie — Montpellier, France (Not_yet_recruiting)
- CHRU de Nîmes - Hôpital Universitaire Carémeau — Nîmes Cedex 09, France (Recruiting)
- Clinique Les Sophoras — Nîmes, France (Not_yet_recruiting)
- Cmme — Paris, France (Recruiting)
- CH Henri Laborit — Poitiers, France (Not_yet_recruiting)
- CHRU de Tours - Clinique Psychiatrique Universitaire — Saint Cyr sur Loire, France (Not_yet_recruiting)
- CHRU de Strasbourg - Hôpital Civil — Strasbourg Cedex, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Mocrane Abbar, MD
- Email: mocrane.abbar@chu-nimes.fr
- Phone: +33.(0)4.66.68.34.26
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.